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The formation of the vascular system begins with vasculo-genesis, the coalescence of endothelial precursor cells to 
form the primitive dorsal aortae, cardinal veins, and the capillary 
plexus of the yolk sac and embryo.1 This primitive vascular net-
work then expands, remodels, and matures into a hierarchically 
organized network of arteries, capillaries, and veins.2 Although 
the phenotypic and genetic differences between endothelial cells 
in different branches of the vasculature were initially thought 
to be downstream of hemodynamic forces, it is now clear that 
arteriovenous differentiation of endothelial cells occurs before 
the onset of blood flow. Notch signaling can activate early arte-
rial gene expression via the Notch transcriptional effector Rbpj 
(CSL) and SoxF factors, suggesting that arterial identity has to be 
acquired and that the default state of endothelial cells is venous.3,4 
However, the vein-specific orphan nuclear receptor COUP-TFII 
(Nr2f2) has been shown to repress arterial gene expression,5 and 
the promotion of venous identity downstream of PI3K (phos-
phoinositide 3-kinase) occurs through inhibition of proarterial 
pathways.6 Consequently, the degree to which particular endo-
thelial cell identities are actively acquired or repressed may vary 
and remains poorly understood.
The vascular endothelial growth factor (VEGF) pathway is 
crucial for vascular development,7 mediating various processes 
in endothelial cells, including sprouting, migration, prolifera-
tion, and differentiation. VEGF signaling has also been impli-
cated in arterial differentiation upstream of Notch, although 
VEGF receptors are found in both arterial and venous endothe-
lial cells.8 In mammals, Flk1 (also known as VEGFR2/KDR), 
a tyrosine kinase receptor, is the main mediator of angiogenic 
growth in response to VEGF-A.7 Flk1−/− mice die before midg-
estation with severe vascular and hematopoietic defects and 
lack mature endothelial cells.9 Zebrafish and other teleosts 
contain 2 orthologues to Flk1, kdr (kdrb) and kdrl (kdra).10 
Although it is kdr that shares direct lineage with mouse Flk1, 
kdrl seems more crucial for zebrafish vascular patterning, sug-
gesting that although the fundamentals of VEGF signaling are 
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conserved between the 2 model systems, the specific roles for 
each receptor may have diverged.11
Previous studies identified a pan-endothelial enhancer within 
the first intron of Flk1 (Flk1intron1)12; however, deletion of this 
enhancer had no detectable effect on Flk1 expression.13 A second 
Flk1 enhancer (Flk1 dorsal multipotent mesodermal enhancer), 
located 5′ upstream of Flk1,14 directs expression in the lateral 
mesoderm during early embryogenesis but not in differenti-
ated endothelial cells.14 Consequently, it is likely that additional 
enhancer elements contribute to Flk1 activity in endothelial cells, 
similar to the multiple endothelial-specific enhancers regulating 
the Mef2c, Tal1, and Dll4 loci.4,15 These arrangements of enhanc-
ers, binding a varied array of transcription factors downstream of 
multiple signaling inputs, may explain the considerable pheno-
typic heterogeneity of endothelial cells among tissues, develop-
mental stages, and angiogenic status.
Many different signaling cascades, including Wnt, trans-
forming growth factor-β, and Notch, interact with the VEGF 
pathway at multiple stages of vascular development, yet these 
interactions are multifaceted, context dependent, and affect gene 
expression patterns both directly and indirectly.16–18 Given the 
crucial role of VEGF signaling in both developmental and tumor 
angiogenesis, a more complete understanding of the manner in 
which components of the VEGF pathway are regulated is key to 
our understanding of how vascular signaling pathways interact to 
pattern the embryonic vasculature correctly, as well as our ability 
to modulate vessel growth accurately in pathological conditions.
Materials and Methods
Materials and Methods are available in the online-only Data 
Supplement.
Results
Identification of an Arterial-Restricted 
Endothelial Cell Enhancer Within the 
10th Intron of the Flk1 Gene
An in silico search of the mouse and human Flk1/KDR loci 
for conserved sequences enriched in enhancer-associated his-
tone modifications and endothelial cell–specific DNaseI hyper-
sensitivity sites identified the 10th intron of Flk1 (Flk1in10) 
as a putative enhancer region (Figure I in the online-only 
Data Supplement19). To verify and characterize the activ-
ity of this region, the 825-bp mouse Flk1in10 sequence was 
cloned upstream of the silent hsp68 minimal promoter and 
LacZ reporter gene and used to generate the stable transgenic 
mouse line Flk1in10:LacZ (Figure 1A). Analysis of embryonic 
Flk1in10:LacZ mice clearly demonstrated enhancer activity in 
the developing vasculature and heart (Figure 1B–1K; Figure 
IIA in the online-only Data Supplement). At embryonic day (E) 
9, activity of the Flk1in10 enhancer was detected throughout 
the endothelial cells of the vasculature, including both venous 
and arterial compartments (Figure 1C and 1G). However, in 
E10 embryos, enhancer activity was stronger in arterial endo-
thelial cells, and by E12, LacZ reporter gene expression was 
only detected in the arterial vasculature. Arterial vascular 
expression was maintained throughout development, although 
expression was absent in certain tissue beds, most notably the 
lung (Figure 1D–1F and 1H–1K; Figure IIB in the online-
only Data Supplement). Furthermore, transgene expression 
decreased after birth and was absent in adult organs (Figure IIB 
in the online-only Data Supplement). These results indicate that 
the Flk1in10 sequence represents a developmental endothelial 
enhancer which becomes restricted to the arterial compartment.
To test whether the mouse Flk1in10 enhancer sequence 
also drives endothelial expression in transgenic zebrafish, it was 
cloned upstream of the E1b minimal promoter20 and green fluo-
rescent protein (GFP) reporter gene (Figure 2A) and used to gen-
erate the tg(Flk1in10:GFP) transgenic fish line. This line was 
then crossed with the pan-endothelial tg(kdrl:HRAS-mCherry) 
line21 to enable analysis of GFP expression patterns within the 
vasculature (Figure 2B–2F). GFP expression was detected in 
the axial, intersegmental, and head vessels; blood cells; and the 
heart, suggesting that the transcriptional pathways regulating 
mouse Flk1in10 are conserved in zebrafish. At 48 hours post 
fertilization, reporter gene expression within the axial vessels 
diminished and was detected weakly only in the dorsal aorta. 
Furthermore, GFP expression became restricted to efferent inter-
segmental vessels (Figure 2D; Movie I in the online-only Data 
Supplement). Restriction of the transgene to the intersegmental 
arteries but not intersegmental veins was also clearly detected at 
72 hours post fertilization, although expression was now mostly 
absent in the axial vessels (Figure 2E and 2F; Figure III in the 
online-only Data Supplement). To rule out a role for flow in the 
establishment of this expression pattern, transgene expression 
was investigated in embryos lacking heart function. Although 
the absence of flow resulted in a decrease in GFP intensity, arte-
rial restriction in the intersegmental vessels was still observed 
(Figure IV in the online-only Data Supplement).
These results demonstrate that Flk1in10 represents a novel, 
arterial-restricted gene enhancer, unlike the Flk1 intron1 enhancer, 
which directs pan-vascular expression12 (Figure V in the online-only 
Data Supplement). This supports the hypothesis that regulation of 
Flk1 in the vasculature is achieved by several modular enhancer ele-
ments and suggests that VEGF receptor availability can be regulated 
independently in different endothelial subpopulations. Although 
endogenous mouse Flk1 mRNA is found in both arterial and venous 
endothelial cells during embryonic development,9 interactome stud-
ies mapping gene regulatory domains have clearly demonstrated 
the association of widely expressed genes with multiple cell type–
specific enhancers,22 and endothelial subtype–specific enhancers 
have been reported for other pan-vascular transcribed genes.23
Flk1in10 Enhancer Contains Functional 
Binding Motifs for Ets, Gata, Rbpj, SoxF, 
and FoxC Transcription Factors
The mouse Flk1in10 enhancer shares significant sequence 
conservation between mammals and birds, but no detectable 
Nonstandard Abbreviations and Acronyms
E embryonic day
EMSA electrophoretic mobility shift assay
GFP green fluorescent protein
NICD Notch intracellular domain
VEGF vascular endothelial growth factor
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conservation to reptiles or fish (Figure IA and IB in the 
online-only Data Supplement). We used ClustalW analysis24 
to analyze the conserved enhancer sequences and identified 
conserved putative binding motifs for Ets, Gata, Rbpj, Sox, 
and Fox, which were then functionally verified by electropho-
retic mobility shift assays (EMSAs) using members of each 
transcription factor family known to be expressed in endothe-
lial cells (Figure 3A–3D). Additional, less conserved motifs 
for Ets (ETS-a, c, e, i, and j), Gata (GATA-a and d), and Rbpj 
(RBPJ-b) were also tested in EMSA to ensure that functional 
yet poorly conserved binding sites were not overlooked. Five 
putative ETS motifs directly bound the Ets factor Etv2 (ETS-f, 
g, h, k, and l; Figure 3B), and 3 of 4 GATA motifs within the 
conserved enhancer directly bound Gata2 (GATA-b, c, and d; 
Figure 3C). All 3 putative SOX motifs directly bound Sox7 
(SOX-a, b, and c), and both putative RBPJ motifs directly 
bound the protein (Figure 3C and 3D). The ETS-h motif was 
directly adjacent to a putative Forkhead binding site (FOX-b), 
forming a FOX:ETS motif (Figure 3).25 However, although a 
composite oligo containing both FOX-a and b motifs bound 
Foxc2, mutations to the FOX-b site did not ablate this binding 
(Figure 3D), suggesting that only the distal FOX-a site was 
required for Foxc2 binding and that the putative FOX:ETS 
motif may not be functional.
Flk1in10 Enhancer Activity Requires Both 
ETS and GATA Transcription Factors
Several Ets transcription factors play crucial roles in vascular 
specification, and all described endothelial cell enhancers con-
tain multiple ETS-binding motifs.15 To confirm that Ets bind-
ing was required for Flk1in10 activity, all 5 functional ETS 
motifs were mutated (sequence information is available in the 
Materials and Methods in the online-only Data Supplement; 
EMSA was used to validate all mutations), and activity of 
the modified mouse enhancer (mutETS-f, g, h, k, and l) was 
tested in transgenic zebrafish (Figure 4A). As expected, the 
ablation of the functional ETS motifs resulted in a total loss of 
enhancer activity in the vasculature, supporting the essential 
role of Ets factors in vascular gene activation.
Both the Flk1 intron1 and dorsal multipotent mesoder-
mal enhancers also contain conserved GATA motifs,12,14 and 
enforced Gata2 expression can induce Flk1 expression in 
hemangioblast culture conditions.26 To study the potential 
role for Gata transcription factors in the direct activation 
of the Flk1in10 enhancer, we mutated all GATA-binding 
motifs within the enhancer and tested the activity of the 
modified enhancer (mutGATA-all) in transgenic zebraf-
ish, analyzing multiple transient transgenic embryos to 
overcome any variability from random transgene integra-
tion (Figure 4A). Mutation of all GATA motifs resulted 
in a severe reduction in vascular enhancer activity, and no 
transgenic fish expressed the reporter gene robustly in the 
vasculature (Figure 4A). Furthermore, mutation of just the 
2 conserved motifs, GATA-b and GATA-c (mutGATA-b,c), 
resulted in similar patterns of expression, although a low 
percentage of transgenic fish had detectable enhancer activ-
ity in intersegmental vessels (Figure 4A). To confirm these 
observations, we generated 11 mouse embryos transgenic 
for the Flk1in10mutGATA-b,c construct (Figure 4B–4F). 
All transgenic embryos showed detectable enhancer activ-
ity, but vascular expression was nearly entirely ablated 
in these embryos, limited to weak expression in a small 
number of vessels within the head region of 2 embryos 
(Figure 4C and 4D). In the remaining 9 transgenic embryos, 
enhancer activity was completely restricted to nonvascular 
tissues (Figure 4E and 4F).
Figure 1. The mouse Flk1in10 enhancer 
directs arterial-restricted expression in trans-
genic mice. A, Schematic representation of 
the mouse Flk1in10 enhancer (top line, exons 
are black boxes) and Flk1in10:LacZ trans-
gene (bottom line). B–K, The Flk1in10:LacZ 
transgene directs arterial expression. Rep-
resentative whole-mount embryos and yolk 
sac tissue from the Flk1in10:LacZ transgenic 
line (B–F) show reporter gene expression 
(X-gal staining, blue) in the vasculature from 
embryonic day 8 (E8) to E16. X-gal staining is 
initially detected throughout the vasculature 
but becomes restricted to the arterial com-
partment during development. G–J, In trans-
verse sections through E9–E12 transgenic 
embryos, X-gal staining is detected in both 
cardinal vein and dorsal aorta at E9 (G) but is 
stronger in the dorsal aorta by E10 and is not 
detected in the venous or lymphatic vascula-
ture by E12. K, E12 transverse paraffin sec-
tions showed that expression of the venous 
marker endomucin does not overlap with that 
of the β-galactosidase reporter gene. a indi-
cates artery; al, allantois; ca, carotid artery; 
cv, cardinal vein; da, dorsal aorta; jls, jugular 
lymph sac; jv, jugular vein; np, neural plexus; 
and v, vein.
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We next examined the consequences of morpholino 
knockdown of the zebrafish gene gata2a on the expres-
sion of the tg(Flk1in10:GFP) fish line (Figure 4G and 4H). 
Gata2a homozygous mutant zebrafish display defective 
trunk circulation and aorta morphogenesis defects, suggest-
ing a role for Gata2 in arterial differentiation,27 although 
arterial and venous markers were unaffected.27 Knockdown 
of gata2a in tg(Flk1in10:GFP) transgenic zebrafish resulted 
in reduction (at low morpholino concentration) and ablation 
(at high morpholino concentration) of reporter gene expres-
sion (Figure 4G). Similar to gata2a mutant fish, arterial and 
venous differentiation occurred normally after morpholino-
induced gata2a knockdown, and arterial–venous identity was 
maintained (Figure VI in the online-only Data Supplement). 
Because kdr, not kdrl, is the evolutionarily conserved ortho-
logue of mouse Flk1, we also investigated whether gata2a 
depletion altered kdr expression. Similar to previous reports 
for kdrl (the functional equivalent of Flk1 in fish), expres-
sion of kdr was notably reduced, but not ablated, after gata2a 
depletion (Figure 4H). Conversely, knockdown of the related 
gata1a gene did not affect reporter gene expression (Figure VI 
in the online-only Data Supplement). These results support a 
requirement for Gata transcription factor binding for vascular-
specific activity of the Flk1in10 enhancer.
Arterial Restriction of Flk1in10 Enhancer Activity 
Is Achieved by RBPJ-Mediated Repression in Veins
Ets and Gata transcription factors are expressed throughout 
the vasculature28,29 and regulate many enhancers active in 
both arterial and venous endothelial cells.25 Consequently, we 
hypothesized that additional binding motifs within Flk1in10 
may be responsible for the arterial restriction of enhancer 
activity. We have previously demonstrated that activity of the 
arterial-specific Dll4 enhancer, which is regulated by Notch 
intracellular domain (NICD) and SoxF factors, requires func-
tional binding motifs for both Rbpj and SoxF transcription 
factors.4 Therefore, we investigated the role of the RBPJ- and 
SOXF-binding motifs in the Flk1in10 enhancer. Surprisingly, 
unlike for the Dll4 enhancer, mutations to all RBPJ and 
SOX motifs (mutRBPJ;mutSox) did not result in the abla-
tion of transgene expression in transgenic zebrafish and mice 
(Figure 5A–5D). However, in contrast to E12 mice transgenic 
for the Flk1in10 wild-type (Flk1in10-WT) enhancer, in which 
enhancer activity was restricted to arterial endothelial cells, 
the Flk1in10mutRBPJ/mutSox enhancer directed reporter 
gene expression to both arterial and venous endothelial cells. 
These results suggest that either the RBPJ or SOX motifs bind 
factors that repress the activity of the Flk1in10 enhancer in 
venous endothelial cells.
Because SoxF transcription factors are primarily arterial 
in mammals,30 we tested a second construct in which only the 
RBPJ sites were mutated (mutRBPJ). Again, expansion of 
enhancer activity into venous endothelial cells was seen in the 
majority of transgenic mice, suggesting that venous repres-
sion of Flk1in10 was mediated by Rbpj binding (Figure 5E). 
Of the 2 functional RBPJ motifs in the Flk1in10 enhancer, 
RBPJ-b bound most robustly in EMSA (Figure 3C). However, 
this motif was not well conserved in the Flk1in10 chicken 
Figure 2. The mouse Flk1in10 enhancer directs arterial-restricted 
expression in transgenic zebrafish. A, Schematic representa-
tion of the Flk1in10:GFP transgene. B, The mouse Flk1in10:GFP 
transgene directs endothelial cell–specific expression in transgenic 
zebrafish line tg(Flk1in10:GFP) at 24 h post fertilization (hpf). C–E, 
Tg(Flk1in10:GFP;kdrl:HRAS:mCherry) zebrafish expresses GFP in 
most endothelial cells at 30 hpf (C). At 48 hpf, GFP expression in 
the axial vessels becomes restricted to the dorsal aorta and to a 
subset of intersegmental vessels, corresponding to the developing 
intersegmental arteries (ISA; D; see also Movie I in the online-only 
Data Supplement). At 72 hpf, little dorsal aorta expression could 
be detected, while GFP expression is maintained in the ISA and 
dorsal longitudinal anastomotic vessel (E). F, Bar chart detailing 
GFP expression pattern in the ISA and intersegmental veins (ISVe) 
at 72 hpf. Represents a total of 18 embryos, ISA and ISVe identity 
established by using kdrl:HRAS-mCherry expression to deter-
mine whether each vessel connected to dorsal aorta or posterior 
cardinal vein. Any detectable level of GFP expression constituted 
positive, and Figure III in the online-only Data Supplement details 
analysis methods. bc indicates blood cells; da, dorsal aorta; 
dlav, dorsal longitudinal anastomotic vessel; dv, dorsal vein; GFP, 
green fluorescent protein; isv, intersegmental vessels; ISVe, inter-
segmental vein; and vv, ventral vein.
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Figure 3. The Flk1in10 enhancer contains 
cis-motifs that bind Etv2, Gata2, Rbpj, Sox7, 
and Foxc2 transcription factors. A, Multispe-
cies alignment of the conserved region of the 
Flk1in10 enhancer. Colored sequences depict 
confirmed consensus binding motifs, and gray 
sequences depict motifs that did not bind in 
electrophoretic mobility shift assay. B, Radio-
labeled oligonucleotide probes encompass-
ing Flk1in10 ETS-f (lanes 1–4), ETS-g (lanes 
5–8), ETS-h (lanes 9–12), ETS-k (lanes 13–16), 
and ETS-l motifs (lanes 17–20) were bound to 
recombinant Etv2 proteins. All proteins efficiently 
bound to labeled probes (lanes 2, 6, 10, 14, and 
18) were competed by excess unlabeled self-
probe (wt, lanes 3, 7, 11, 15, and 19) but not by 
mutant self-probe (mu, lanes 4, 8, 12, 16, and 
20). C, Radiolabeled oligonucleotide probes 
encompassing Flk1in10 GATA-b (lanes 1–4), 
GATA-c (lanes 5–8), GATA-d (lanes 9–12), RBPJ-
a (lanes 13–16), and RBPJ-b motifs (lanes 17–20) 
were bound to recombinant Gata2 and Rbpj 
proteins. All proteins efficiently bound to labeled 
probes (lanes 2, 6, 10, 14, and 18) were com-
peted by excess unlabeled self-probe (wt, lanes 
3, 7, 11, 15, and 19) but not by mutant self-probe 
(mu, lanes 4, 8, 12, 16, and 20). D, Radiolabeled 
oligonucleotide probes encompassing Flk1in10 
SOX-a (lanes 1–4), SOX-b (lanes 5–8), SOX-c 
(lanes 9–12), and FOX-a/b (lanes 13–19) were 
bound to recombinant Sox7 and Foxc2 proteins. 
All proteins efficiently bound to labeled probes 
(lanes 2, 6, 10, and 14) were competed by 
excess unlabeled self-probe (wt, lanes 3, 7, 11, 
and 16) but not by mutant self-probe (mu, lanes 
4, 8, and 12). For FOX-a/b, mutant self-probe 
with mutations to both FOX motifs (mu A+B) 
or to FOX-a could not compete with labeled 
probes (17, 19), whereas a mutant self-probe 
with mutations to FOX-b (mu B) was still able to 
robustly compete with labeled probe (18). mu 
indicates mutant; ns, nonspecific binding; and 
wt, wild-type.
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enhancer sequence, and the orthologous chicken RBPJ-b 
motif could not directly bind RBPJ in EMSA (Figure VIIA in 
the online-only Data Supplement). Therefore, we also tested 
the activity of the orthologous chicken Flk1in10 enhancer. 
Similar to mouse Flk1in10mutRBPJ, the chicken enhancer 
was robustly active in both arterial and venous endothelial cells 
(Figure 5F; Figure VIIB in the online-only Data Supplement). 
These results indicate that functional RBPJ-binding motifs are 
required for the repression of Flk1in10 enhancer activity in 
venous endothelial cells. Although Rbpj forms an activation 
complex with NICD, it can also inhibit transcription through 
the binding of corepressors and recruitment of repression 
complexes in the absence of NICD.31 Because the expression 
of Notch receptors Notch1 and Notch4 is greatly enriched in 
the arterial endothelium, our results suggest that the low lev-
els of Notch signaling in venous cells result in the formation 
of repressive complexes at the RBPJ motifs of the Flk1in10 
enhancer. Supporting this, chromatin immunoprecipitation 
Figure 4. The Flk1in10 enhancer requires 
ETS and GATA motifs for endothelial expres-
sion. A and B, Summary of reporter gene 
expression detected in (A) 48 hpf Tol2-medi-
ated mosaic transient transgenic zebrafish 
embryos and (B) E12 transient transgenic 
mice. Asterisk indicates weak staining in 
head region only. C–F, Whole-mount (top) 
and transverse sections (bottom) of rep-
resentative E12 X-gal–stained embryos 
transgenic for the Flk1in10mutGATA-b,c 
construct. Depicted sections correspond 
to the embryos shown. Number in bottom 
corner of whole-mount embryo denotes 
the number of embryos similar to that 
shown. Lines marked i and ii on C mark the 
approximate location of transverse sections. 
Arrowheads mark head vessels. G, Analysis 
of scrambled, 1.125 ng, 2.25 ng, and 3.375 
ng gata2a morpholino (MO) in 48 h post fer-
tilization (hpf) tg(Flk1in10:GFP) embryos. H, 
Analysis of scrambled, 2.25 ng and 3.375 ng 
gata2a MO in 26 hpf WT zebrafish embryos, 
using whole-mount kdr in situ hybridization. 
cv indicates cardinal vein; da, doral aorta; 
and GFP, green fluorescent protein.
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Figure 5. Rbpj is required for arterial restriction 
of the Flk1in10 enhancer. A and B, Summary of 
reporter gene expression detected in (A) 48 h post 
fertilization (hpf) Tol2-mediated mosaic transient 
transgenic zebrafish embryos and (B) embryonic 
day (E) 12 transient transgenic mice. C–F, Whole-
mount (top) and transverse sections (bottom) 
of representative E12 X-gal–stained transient 
transgenic embryos expressing mouse Flk1in10 
WT (C), mouse Flk1in10mRBPJ/SOX (D), mouse 
Flk1in10mRBPJ (E), and chicken Flk1in10 WT (F). 
Lines marked i and ii on C mark the approximate 
location of transverse sections in C–F. a indicates 
artery; cv, cardinal vein; da, dorsal aorta; and v, 
veins. G–I, Analysis of the effects of scrambled 
(G), 1.25 ng rbpj morpholino (MO) oligonucle-
otides (H), and Notch signaling inhibitor N-[N-
3,5-difluorophenacetyl]-l-alanyl-S-phenylglycine 
methyl ester (DAPM) (I) in 72 h post fertilization 
(hpf) tg(Flk1in10:GFP) embryos. MO-mediated 
knockdown of rbpj results in expansion of 
Flk1in10:GFP expression into the caudal vein, the 
posterior cardinal vein, and intersegmental vein. 
da indicates dorsal aorta; GFP, green fluorescent 
protein; ISA, intersegmental artery; ISVe, interseg-
mental vein; and pcv, posterior cardinal vein.
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studies in mouse venous and arterial endothelial cells dem-
onstrated that, although Rbpj can bind the Flk1in10 enhancer 
in both cell types, NICD is bound only in arterial endothelial 
cells (Figure VIIC in the online-only Data Supplement).
To further investigate the role of Rbpj/Notch in the regula-
tion of Flk1in10, we examined the consequences of morpho-
lino-induced rbpj knockdown in tg(Flk1in10:GFP) zebrafish 
(Figure 5G and 5H). In direct agreement with our transgene 
manipulation data, the depletion of Rbpj resulted in an expan-
sion of Flk1in10:GFP expression into venous endothelial 
cells. This was also accompanied by a slight increase in GFP 
intensity, potentially a result of the increased cell proliferation 
and sprouting which occurs after Rbpj depletion.32 We next 
investigated the consequences of inhibiting NICD transloca-
tion to the nucleus by treating the tg(Flk1in10:GFP) embryos 
with the γ-secretase inhibitor N-[N-3,5-difluorophenacetyl]-
l-alanyl-S-phenylglycine methyl ester (DAPM). Unlike the 
depletion of Rbpj, this chemical treatment was not expected 
to affect venous expression of Flk1in10 because Notch signal-
ing is not active in the venous vasculature.33 Strikingly, DAPM 
treatment resulted in the compete ablation of Flk1in10:GFP 
expression at 72 hours post fertilization (Figure 5I), provid-
ing further evidence that Rbpj is able to repress Flk1in10 
expression in the absence of Notch signaling. A schematic 
model summarizing these results is found in Figure VIII in the 
online-only Data Supplement.
Potential Roles for Sox and Notch in Promoting 
Activity of Flk1in10 in Arterial Cells
Although our results suggest that only Ets and Gata factors 
transcriptionally activate Flk1in10 expression in endothelial 
cells, this may not preclude the involvement of other posi-
tive regulatory factors. All 3 characterized Flk1 enhancer 
elements contain essential ETS- and GATA-binding motifs, 
yet the activity of these enhancers overlaps only during the 
very early stages of vascular development. Because intact 
Notch signaling, essential for arterial differentiation, is itself 
downstream of VEGF through the Flk1 receptor,8 and loss 
of Notch signaling resulted in ablation of Flk1in10:GFP 
expression at 72 hours post fertilization, we wanted to 
investigate whether Rbpj/NICD binding could also provide 
a positive input to the Flk1in10 enhancer. The potential for 
such a role is supported by recent analysis of other arterial-
restricted enhancers that have demonstrated activating roles 
for Rbpj/Notch and SoxF factors.4,23 The loss of Flk1in10 
expression after DAPM-mediated sequestration of NICD 
suggested a possible positive role for Notch, yet these results 
may merely represent the acquisition of repression, not the 
loss of activation, and are not supported by the Rbpj mor-
pholino results. However, loss of Rbpj in zebrafish resulted 
in a hyper-sprouting phenotype that may have also indirectly 
activated Gata-mediated Flk1in10 activity. Furthermore, 
analysis of mutations in the background of numerous ETS 
and GATA motifs created in multiple-copy transgenic mice 
and fish may inadvertently mask the minor effects of acces-
sory transcriptional activators.
Consequently, we studied the potential positive role of 
Rbpj/NICD and SoxF on Flk1in10 by analyzing the effects 
of partial depletion of GATA in conjunction with RBPJ and 
SOX on Flk1in10 activity in transgenic zebrafish and mice. 
First, we generated a Flk1in10 construct in which one con-
served GATA site (GATA-c) was left functional, whereas 
the other sites were mutated (mutGATAa,b,d). In both 
transgenic zebrafish and mice, the presence of a single func-
tional GATA-c site resulted in increased enhancer activity 
in endothelial cells compared with mutGATA-all and mut-
GATA-b,c (Figure 6A–6E compared with Figure 4A and 
4B). However, the expression levels were reduced com-
pared with the WT Flk1in10 enhancer (Figure 6A and 6B). 
We further mutated this construct to also ablate the binding 
sites for SOX and RBPJ, creating Flk1in10mutGATA-a,b,d/
RBPJ/SOX. Surprisingly, the additional mutation of the 
SOX and RPBJ sites resulted in a complete loss of reporter 
gene expression in both zebrafish and mouse transgenic 
embryos (Figure 6). These results suggest that, when the 
absolute binding levels of Gata are reduced, Rbpj/NICD 
and SoxF factors may play a transcriptionally activating 
role. Further transgenic analysis, this time using Flk1in10 
constructs containing alternative mutations ablating either 
the GATA-b motif alone or in combination with SOX and 
RBPJ, resulted in similar patterns of transgene expres-
sion in both zebrafish and mouse models (Figure 6). These 
results therefore suggest that the RBPJ- and SOX-binding 
motifs, although not sufficient for enhancer activity alone, 
may provide the Flk1in10 enhancer with some level of pos-
itive regulatory input in arterial endothelial cells, along-
side the more important role of Rbpj in the suppression of 
Flk1in10 in the vein.
Discussion
In this study, we have identified a novel endothelial cell 
enhancer within the 10th intron of Flk1. Similar to other Flk1 
regulatory elements, this enhancer requires both Ets- and Gata-
binding motifs for transcriptional activity. However, Flk1in10 
enhancer activity was restricted to the arterial compartment 
through both repressive and activating signals downstream of 
Rbpj/Notch and Sox regulatory pathways, demonstrating a 
direct link between the Notch and VEGF signaling pathways, 
and a novel regulatory role for Rbpj in repression of arterial 
identity in venous endothelial cells.
We have previously described an enhancer for the 
Notch ligand Dll4 (Dll4in3) which is also active in arte-
rial endothelial cells.4,34 Although both enhancers can 
be described as directing arterial expression within the 
vasculature, they do not direct identical expression pat-
terns: Dll4in3 is arterial specific throughout develop-
ment, whereas Flk1in10 starts pan-vascular then gradually 
becomes arterially restricted. It is therefore unsurpris-
ing that the transcriptional mechanisms regulating these 
2 enhancers are divergent. Rbpj plays no clear repressive 
role in Dll4in3 regulation, although Notch-dependent Rbpj 
activation in combination with SoxF factors is essential 
for enhancer activity. Conversely, our study demonstrates 
a role for Rbpj in repression of Flk1 expression in veins, in 
line with the view of Rbpj as a mediator of default repres-
sion in the absence of Notch signaling.31 These differences 
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in expression outcome likely reflect the distinct upstream 
signals regulating the Notch and VEGF pathways in vas-
cular development and further support the idea that neither 
the venous nor the arterial endothelial cell fully represents 
a default vascular state onto which the alternative identity 
is actively acquired.
Although Ets factors have long been known to be crucial 
for endothelial cell specification, recent studies have also 
implicated the Ets factor Erg in arterial specification down-
stream of VEGF.34 Because mutations to Ets-binding motifs 
in Flk1in10 resulted in loss of expression, it remains possi-
ble that Erg may contribute to the arterial-restricted activity 
Figure 6. Ablation of RBPJ and SOX motifs 
alongside perturbation of GATA sites reveals 
a requirement for Rbpj/Notch and SoxF fac-
tors in the activation of Flk1in10 in arteries. 
A and B, Summary of reporter gene expres-
sion detected in (A) 48 h post fertilization 
(hpf) Tol2-mediated mosaic transient trans-
genic zebrafish embryos and (B) embryonic 
day (E) 12 transient transgenic mice. C 
and D, Bar charts representing zebrafish 
(C) and mouse (D) expression patterns of 
Flk1in10 constructs reported in A and B. 
E, Whole-mount embryos (top) and yolk 
sac tissues (bottom) of representative E12 
X-gal–stained transient transgenic embryos 
expressing mouse Flk1in10mutGATA-a,b,d, 
mouse Flk1in10mutGATA-a,b,d/RBPJ/SOX, 
mouse Flk1in10mutGATA-b, and mouse 
Flk1in10mutGATA-b/altRBPJ/altSOX (E). a 
indicates artery; GFP, green fluorescent  
protein; and v, veins.
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of Flk1in10. However, the ETS-binding motifs were present 
and functional in the Flk1in10mutRBPJ/mutSOX enhancer, 
which was active in both arterial and venous endothelial cells, 
and the Flk1in10mutGATA/mutRBPJ/mutSOX enhancer, 
which was not active in endothelial cells at all. Consequently, 
although we cannot absolutely rule out an indirect role for 
Erg, it is clear that ETS motifs are not sufficient to achieve 
arterial specification or enhancer activation in the absence of 
other transcription factors.
Ablation of Gata2 specifically in endothelial cells in both 
mice and zebrafish does not recapitulate the Flk1 null pheno-
type, although later vascular differentiation was impaired.27,35 
Although it is theoretically possible that the Flk1 locus could 
be independent of Gata factors via additional, undiscovered 
regulatory elements, this seems unlikely: all 3 known Flk1 
enhancers require GATA-binding motifs to function, and 
expression of the orthologous kdr and kdrl genes was dimin-
ished in zebrafish after disruption of gata2a. Notably, Gata2 
is not the only member of the Gata family expressed in the 
vasculature: both Gata3 and Gata6 are also expressed in endo-
thelial cells during vascular development.15 Therefore, it is 
likely that additional members of the Gata transcription factor 
family can contribute to Flk1 regulation and at least partially 
compensate in the absence of Gata2.
Although it is known that VEGF and Notch both act in a 
conserved genetic pathway to promote arterial differentiation, 
and VEGF-mediated induction of Notch receptors requires 
intact Notch signaling, some models have suggested that 
Notch signaling can actively represses Flk1 levels. This was 
first proposed in studies of the angiogenic front in the postna-
tal retina, where decreased Notch levels in tip cells correspond 
with increased angiogenic sprouting and filopodia projec-
tions.2 However, the extent of direct Notch inhibition of Flk1 
varies significantly in different experimental contexts, and 
although Flt4 (Vegfr3) expression inversely correlates with 
areas active in Notch signaling, the same is not true for Flk1.16 
It is therefore likely that any repression of Flk1 expression 
downstream of active Notch during angiogenesis may reflect 
indirect repression via Flt4 instead of active Notch-mediated 
repression of Flk1 expression.16,36
Although enhancer studies primarily focus on the tran-
scription factors essential for activity, it is likely that much 
of the crucial information governing vascular differentiation, 
patterning, and tissue specificity comes from nonessential, 
and consequently harder to assay, regulatory inputs. This 
research demonstrates that enhancer regulation of Flk1 is 
more nuanced, and more complicated, than a simple on/off 
transcription factor switch, reflecting the reality of expres-
sion of an essential and multifaceted receptor within the het-
erogenous vasculature. Multiple enhancers, binding multiple 
transcription factors, permit different layers of transcrip-
tional regulation and allow many different upstream cues to 
subtly alter expression levels. The arrangement of binding 
motifs within the Flk1in10 enhancer may enable Notch sig-
naling to subtly suppress Flk1 expression in venous cells, 
whereas amplifying it in arterial cells, therefore providing a 
way to ensure correct arterial–venous differentiation without 
detrimentally influencing the other essential functions of the 
VEGF pathway in the vasculature.
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